Scientists have developed an experimental gene therapy with the potential to treat early-onset Parkinson’s disease associated with PRKN gene mutations, according to a new preclinical study. Delivery of the gene therapy carrying a functional version of the PRKN gene into the brains of two mouse…
News
Biological changes associated with Parkinson’s disease, including newly identified changes in a signaling network linked to neuroinflammation, or brain inflammation, may begin up to 12 years before diagnosis. That’s according to data from a proof-of-concept study of Grifols’ Chronos-PD research initiative, which aims to identify biomarkers that…
GT-02287, an oral Parkinson’s disease therapy from Gain Therapeutics, showed promising results in a Phase 1b trial. Over three months of treatment, patients had lower levels of DOPA decarboxylase (DDC) in their cerebrospinal fluid — a biomarker linked to Parkinson’s activity. Motor function remained stable over five months of treatment.
Young adults with autism may show abnormalities in the activity of dopamine transporters — proteins that recycle dopamine after its release in the brain — that are commonly associated with Parkinson’s disease, according to a recent study. Using dopamine transporter imaging scans, or DaTscan, researchers identified abnormalities in…
GEN Pharmaceuticals has received ethical approval from an accredited medical research ethics committee in the Netherlands to conduct a small clinical trial testing SUL-238, its investigational medication for Parkinson’s disease. With this approval, the company will activate a clinical site in Groningen in the northern Netherlands with patient…
Vima Therapeutics is gearing up to launch a Phase 2 clinical trial this year to evaluate VIM0423, its potential first-in-class once-daily oral therapy for dystonia, or abnormal muscle tone, associated with Parkinson’s disease. Meanwhile, the first participant has been dosed in Stride Dystonia, a Phase 2…
Casma Therapeutics has been awarded $7.6 million from The Michael J. Fox Foundation (MJFF) to support the preclinical development of its CSM-101 therapy candidate for Parkinson’s disease. The funding includes a $2.1 million grant under the Targets to Therapies Initiative, which will be used for helping…
The integration of Kneu Health’s smartphone-based platform into Cedars-Sinai’s Parkinson’s care program enabled ongoing symptom monitoring and revealed the need for earlier intervention in 79% of encounters. According to the company, clinicians reported that the added insight helped care teams monitor treatment responses and inform more timely, personalized…
Immunis said it entered into an exclusive deal with Toray for the rights to develop and commercialize a potential treatment for dyskinesia, the involuntary movements associated with long-term use of levodopa in people with Parkinson’s disease, and has submitted an application to the U.S. Food…
Oncodesign Precision Medicine (OPM) has been awarded a $6.92 million research grant from The Michael J. Fox Foundation (MJFF) to prepare its LRRK2 inhibitor, OPM-201, for a clinical study in people with early Parkinson’s disease. The funding follows OPM’s integration into MJFF’s LRRK2 Investigative Therapeutics Exchange…
Recent Posts
- When it comes to Parkinson’s, hope is not a plan, but urgent action is
- My uncle’s Parkinson’s progression changed some things, but not others
- Gene therapy shows promise for early-onset Parkinson’s in lab study
- New study finds early Parkinson’s signals in blood years before symptoms
- The nudge I needed to better manage my anxiety with Parkinson’s